Search clinical trials for: Phospholipase

Total 50 results

HK inno.N Corporation

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Mild to Moderate Atopic Dermatitis
Ophirex, Inc.

Recruiting

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) (BRAVIO)

Snakebite | Envenoming, Snake

United States
HK inno.N Corporation

Recruiting

A Study to Investigate the Effect of Food on the Pharmacokinetics of IN-A002 Capsule in Healthy Male Subjects

Healthy

Korea, Republic of
Centre Hospitalier Universitaire de Nice

Completed

Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation (PRAM-KT)

Kidney Transplantation

France
Ophirex, Inc.
Premier Research Group plc

Terminated

Study of Varespladib in Patients Hospitalized With Severe COVID-19 (STAIRS)

Coronavirus Disease 2019 | Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2

United States
Ophirex, Inc.
Premier Research Group plc

Completed

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO)

Snakebites | Envenoming | Envenoming, Snake | Envenomation, Snake

United States, India
Nanjing First Hospital, Nanjing Medical University

Completed

Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes

Type2 Diabetes
All India Institute of Medical Sciences, New Delhi

Completed

Candida Associated Cytokines in Oral Leukoplakia

Oral Leukoplakia

India
Kanuni Sultan Suleyman Training and Research Hospital

Completed

Preeclamptic Patients and Pentraxin 3 & Lipoprotein-associated Phospholipase A2

Pre-Eclampsia

Turkey
National Institute of Mental Health (NIMH)

Completed

PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Volunteer

United States
Virginia Commonwealth University

Completed

sPLA2 in EBC During Acute Chest Syndrome

Sickle Cell Disease | Acute Chest Syndrome

United States
National Institute of Neurological Disorders and...

Completed

Positron Emission Tomography (PET) to Study Brain Signaling

Healthy

United States
GlaxoSmithKline

Completed

Integrated Biomarker And Imaging Study - 2

Atherosclerosis

Netherlands, Belgium, Germany, Czechia, France, Austria, Spain, Norway, Poland, Denmark, Switzerland
GlaxoSmithKline

Completed

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

Atherosclerosis

Japan
GlaxoSmithKline
The TIMI Study Group

Completed

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

Acute Coronary Syndrome

United States, France, Netherlands, Ukraine, Germany, Taiwan, Bulgaria, Hungary, Poland, Russian Federation, Argentina, Belgium, Peru, Philippines, Sweden, Thailand, Israel, Spain, Korea, Republic of, Australia, Czechia, Japan, New... and more
GlaxoSmithKline

Completed

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY)

Atherosclerosis

United States, Argentina, Australia, France, Germany, Netherlands, Taiwan, Bulgaria, Estonia, Poland, Russian Federation, Spain, Belgium, Canada, Peru, Philippines, Sweden, Thailand, Korea, Republic of, Hong Kong, Hungary, Slovakia, Ukrain... and more
GlaxoSmithKline

Completed

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

Atherosclerosis

United States
GlaxoSmithKline

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

Atherosclerosis

United States
GlaxoSmithKline

Completed

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

Atherosclerosis

United States
GlaxoSmithKline

Completed

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Atherosclerosis

United States
GlaxoSmithKline

Completed

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

Atherosclerosis

United Kingdom
GlaxoSmithKline

Completed

Darapladib China PK

Atherosclerosis

China
GlaxoSmithKline

Completed

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

Atherosclerosis

United States
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline; National...

Completed

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

Endothelial Dysfunction

United States
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Glomerulonephritis, Membranous

Australia, Spain, United States, Canada, Germany, Netherlands, France, United Kingdom, Czech Republic, Italy
GlaxoSmithKline

Completed

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

Atherosclerosis

United States
GlaxoSmithKline

Completed

A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Retinopathy, Diabetic

Australia, Netherlands, Italy, Germany, Denmark
GlaxoSmithKline

Completed

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

Atherosclerosis

United States
GlaxoSmithKline

Completed

A Study With Darapladib to Collect Tolerability Information

Atherosclerosis

United States
GlaxoSmithKline

Completed

Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

Atherosclerosis

Japan
GlaxoSmithKline

Completed

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

Atherosclerosis

United States
Taizhou Fourth People's Hospital
Shanghai 10th People's Hospital

Unknown

The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris (DOLPHIN)

Inflammation | Angina, Stable

China
Alexhander Izhaki

Completed

ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?

Acute Chest Syndrome

Israel
Instituto Dante Pazzanese de Cardiologia
University of Campinas, Brazil

Completed

Genetical, Anthropometrical and Biochemical Factors Influencing High Risk Subclinical Atherosclerosis

Primary Prevention

Brazil
GlaxoSmithKline

Completed

SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

Coronary Heart Disease
Anthera Pharmaceuticals

Completed

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes (FRANCIS-ACS)

Acute Coronary Syndrome

Russian Federation, Georgia, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (IMPACTS-2)

Sickle Cell Disease | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Sickle Cell Disease | Acute Chest Syndrome | Vaso-occlusive Crisis

United States
Yonsei University

Completed

Dietary Effects on Circulating Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity and Enzyme Activity in Peripheral Blood Mononuclear Cells (PBMCs) in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes

Impaired Fasting Glucose | Newly Diagnosed Type 2 Diabetes

Korea, Republic of
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Preventing Acute Chest Syndrome by Transfusion Feasibility Study (PROACTIVE)

Sickle Cell Disease

United States
Anthera Pharmaceuticals

Terminated

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome (VISTA-16)

Acute Coronary Syndrome

United States, Australia, Canada, Czech Republic, Georgia, Germany, Hungary, India, Italy, Korea, Republic of, Lebanon, Netherlands, New Zealand, Poland, Russian Federation, Spain, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Renal Impairment

United States
Anthera Pharmaceuticals

Completed

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Healthy Volunteers

United States
CAMC Health System

Completed

Phospholipase A2 Producing Bacteria and Pre-Term Labor

Preterm Labor

United States
University Hospital, Aker
University of Oslo; AstraZeneca; Norwegian University of Science and Technology; Diakonhjemmet Hospital and other collaborators

Completed

Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders

Norway
Anthera Pharmaceuticals

Completed

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)

Coronary Artery Disease (CAD)

United States, Ukraine
University Health Network, Toronto
Anthera Pharmaceuticals

Completed

sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial (SPIDER-PCI)

Coronary Artery Disease

Canada
US Department of Veterans Affairs

Completed

Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides

Hypertriglyceridemia

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Topical Antiflammin-2 for Psoriasis

Psoriasis

United States
Anthera Pharmaceuticals

Completed

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

Coronary Artery Disease

United States

Search clinical trials for: Phospholipase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations